TWi Biotechnology, Inc. announced that it is currently seeking participants for a Phase 1 clinical trial of a topical gel called tofacitinib for the treatment of granuloma annulare (GA). The TWiB team and collaborating physicians invite eligible individuals to participate in this study at Yale University Hospital.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.2 TWD | -0.81% | -2.40% | -12.86% |
04-09 | TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-12.86% | 33.29M | |
+52.36% | 56.69B | |
-3.86% | 41B | |
+38.14% | 38.11B | |
-12.01% | 26.89B | |
+14.13% | 25.59B | |
-21.62% | 18.59B | |
+0.21% | 12.39B | |
+25.96% | 11.99B | |
+23.02% | 11.88B |
- Stock Market
- Equities
- 6610 Stock
- News TWi Biotechnology, Inc.
- TWi Biotechnology, Inc. Exploring Promising Treatment for Granuloma Annulare (Ga)